Drug profile

The FDA adverse-event record for Eye Medication

72 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Eye Medication. See the species affected, top reactions, and outcomes below.

72
adverse-event reports
16.7%
death-coded share
Dog
most-reported species
17
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
72
Total Reports
12
Deaths Reported
16.7%
Death Rate

Active Ingredients

Eye Medication

Administration Routes

OphthalmicUnknownIntraocularAuricular (Otic)

Species Affected

Dog 58
Cat 14

Most Affected Breeds

Shih Tzu 9
Domestic Shorthair 7
Maltese 5
Bulldog 3
Spaniel - Cocker American 2
Chihuahua 2
Schnauzer (unspecified) 2
Terrier - Rat 2
Terrier - Yorkshire 2
Retriever - Golden 2

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 17
Weight loss 11
Other abnormal test result NOS 9
Elevated serum alkaline phosphatase (SAP) 9
Anorexia 9
Lack of efficacy - NOS 8
Vomiting 8
Death by euthanasia 6
Emesis 6
Corneal ulcer 6
Abnormal ultrasound finding 6
Elevated alanine aminotransferase (ALT) 6

Outcome Breakdown

Ongoing
35 (48.6%)
Outcome Unknown
15 (20.8%)
Recovered/Normal
9 (12.5%)
Euthanized
6 (8.3%)
Died
6 (8.3%)
Recovered with Sequela
1 (1.4%)

Eye Medication Adverse Event Insights

72 reports name Eye Medication; 12 recorded a death outcome (16.7% of reported events, not a population-level mortality rate). Active ingredient: Eye Medication. Administration routes: Ophthalmic, Unknown, Intraocular, Auricular (Otic).

By species: Dog (58 reports), Cat (14 reports). By breed: Shih Tzu (9), Domestic Shorthair (7), Maltese (5).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (17), Weight loss (11), Other abnormal test result NOS (9), Elevated serum alkaline phosphatase (SAP) (9). Outcome, 72 coded reports: Ongoing leads at 48.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.